

PD-L1 (E1L3N[®]) XP[®] Rabbit mAb (HRP Conjugate)



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity:	Sensitivity: Endogenous	MW (kDa): 40-50	Source/Isotype: Rabbit IgG	UniProt ID: #Q9NZQ7	Entrez-Gene Id: 29126
Product Usage Information		Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 136 mM N 50% glycerol. Store at		mM sodium phosphate ot the antibodies.	(pH 7.4) dibasic, 2 i	mg/ml BSA, and
Specificity/Sensitivity		PD-L1 (E1L3N [®]) XP [®] Rabbit mAb (HRP Conjugate) recognizes endogenous levels of total PD-L1 protein.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PD-L1 protein.				
Description		This Cell Signaling Technology antibody is conjugated to the carbohydrate groups of horseradish peroxidase (HRP) via its amine groups. The HRP conjugated antibody is expected to exhibit the same species cross-reactivity as the unconjugated PD-L1 (E1L3N®) XP® Rabbit mAb #13684.				
Background		Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligand binds the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 was discovered following a search for novel B7 protein homologs and was later shown to be expressed by antigen presenting cells, activated T cells, and tissues including placenta, heart, and lung (1-3). Similar in structure to related B7 family members, PD-L1 protein contains extracellular IgV and IgC domains and a short, cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas (4-6). Expression of PD-L1 in cancer is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma (7). Additional research links PD-L1 expression to cancers associated with viral infections (8,9).				
Background References		1. Dong, H. et al. (1999) <i>Nat Med</i> 5, 1365-9. 2. Freeman, G.J. et al. (2000) <i>J Exp Med</i> 192, 1027-34. 3. Liang, S.C. et al. (2003) <i>Eur J Immunol</i> 33, 2706-16. 4. Dong, H. et al. (2002) <i>Nat Med</i> 8, 793-800. 5. Thompson, R.H. et al. (2006) <i>Cancer Res</i> 66, 3381-5. 6. Pardoll, D.M. (2012) <i>Nat Rev Cancer</i> 12, 252-64. 7. Taube, J.M. et al. (2012) <i>Sci Transl Med</i> 4, 127ra37. 8. Lyford-Pike, S. et al. (2013) <i>Cancer Res</i> 73, 1733-41. 9. Chen, B.J. et al. (2013) <i>Clin Cancer Res</i> 19, 3462-73.				

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

Applications Key

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

W: Western Blotting

Cross-Reactivity Key H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

 ${\tt E1L3N}\ is\ a\ registered\ trademark\ of\ Cell\ Signaling\ Technology,\ Inc.$

XP is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.